- Home
- STTK vs SDST Comparison
STTK vs SDST Comparison
Compare STTK & SDST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- SDST
- Stock Information
- Founded
- STTK 2016
- SDST 2022
- Country
- STTK United States
- SDST United States
- Employees
- STTK N/A
- SDST N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- SDST Blank Checks
- Sector
- STTK Health Care
- SDST Finance
- Exchange
- STTK Nasdaq
- SDST Nasdaq
- Market Cap
- STTK 37.6M
- SDST 33.1M
- IPO Year
- STTK 2020
- SDST N/A
- Fundamental
- Price
- STTK $0.91
- SDST $0.72
- Analyst Decision
- STTK Hold
- SDST Strong Buy
- Analyst Count
- STTK 4
- SDST 2
- Target Price
- STTK $3.00
- SDST $1.73
- AVG Volume (30 Days)
- STTK 108.4K
- SDST 785.4K
- Earning Date
- STTK 05-01-2025
- SDST 05-14-2025
- Dividend Yield
- STTK N/A
- SDST N/A
- EPS Growth
- STTK N/A
- SDST N/A
- EPS
- STTK N/A
- SDST N/A
- Revenue
- STTK $4,606,000.00
- SDST N/A
- Revenue This Year
- STTK N/A
- SDST $4,114.37
- Revenue Next Year
- STTK N/A
- SDST N/A
- P/E Ratio
- STTK N/A
- SDST N/A
- Revenue Growth
- STTK 69.65
- SDST N/A
- 52 Week Low
- STTK $0.69
- SDST $0.41
- 52 Week High
- STTK $11.76
- SDST $28.38
- Technical
- Relative Strength Index (RSI)
- STTK 47.64
- SDST N/A
- Support Level
- STTK $0.84
- SDST N/A
- Resistance Level
- STTK $1.00
- SDST N/A
- Average True Range (ATR)
- STTK 0.09
- SDST 0.00
- MACD
- STTK 0.01
- SDST 0.00
- Stochastic Oscillator
- STTK 42.02
- SDST 0.00
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About SDST Stardust Power Inc. Common Stock
Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).